The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer — AP

Squamous Cell Carcinoma of Esophagus Clinical Trial

Official title:
The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer

Status Completed

Clinical Trial Summary

This is a prospective cohort study on the effect of Andrographis Paniculata (AP) on palliative management of patients with advanced or metastatic esophageal cancer. A total of 30 patients with locally advanced or metastatic squamous esophageal cancer will be recruited for the trial.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Esophageal Neoplasms
Esophageal Squamous Cell Carcinoma
Squamous Cell Carcinoma of Esophagus

Clinical Trial Details

NCT number	NCT04196075
Study type	Interventional
Source	Chinese University of Hong Kong
Contact
Status	Completed
Phase	Phase 3
Start date	March 1, 2018
Completion date	June 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05759325` - An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma
Active, not recruiting	`NCT02353936` - A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus	Phase 2
Withdrawn	`NCT02033538` - Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus	Phase 2
Terminated	`NCT01248299` - Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.	Phase 2
Withdrawn	`NCT02041819` - Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus	Phase 2
Completed	`NCT00165490` - Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer	Phase 2